問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

Digestive System Department

Division of Hematology & Oncology

MacKay Memorial Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

MacKay Memorial Hospital

Division of Hematology & Oncology

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Digestive System Department

更新時間：2023-09-19

蘇建維Su, Chien-Wei
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

11Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇建維

List

39Cases

2009-07-01 - 2011-06-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2011-09-01 - 2013-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2019-10-01 - 2023-07-17

Phase III

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR)

  • Condition/Disease

    D-LIVR

  • Test Drug

    Lonafarnib

Participate Sites
6Sites

Recruiting6Sites

2015-08-01 - 2017-12-31

Phase I

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study To evaluate The Safety, Tolerability, And Immunogenicity Of INO-1800 Alone Or in Combination With INO-9112 Delivered IM Followed By Electroporation In Select Nucleos(t)ide Analogue-Treated, HBeAG-Positive, Chronic Hepatitis B Patients

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    INO-1800 and INO-9112

Participate Sites
6Sites

Terminated5Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

2013-03-31 - 2019-04-30

Phase III

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    Lenvatinib

Participate Sites
12Sites

Not yet recruiting12Sites

2008-12-01 - 2014-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2015-07-01 - 2022-12-31

Phase III

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Ramucirumab (Cyramza)

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2017-05-01 - 2025-12-31

Others

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

  • Condition/Disease

    Nonalcoholic Steatohepatitis

  • Test Drug

    CVC /150mg tablet

Participate Sites
13Sites

Not yet recruiting9Sites

Recruiting1Sites

Terminated1Sites

彭成元
China Medical University Hospital-Taipei

未分科

2016-07-01 - 2020-01-31

Others

A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis (NASH)

  • Condition/Disease

    non-alcoholic steatohepatitis (NASH)

  • Test Drug

    LJN452 (tropifexor)

Participate Sites
8Sites

Terminated6Sites

黃志富
Kaohsiung Municipal Gangshan Hospital

未分科

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2009-09-01 - 2018-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Suspended3Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB